Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1950 1
1951 4
1953 3
1954 5
1955 6
1956 10
1957 9
1958 8
1959 6
1960 13
1961 21
1962 27
1963 38
1964 101
1965 50
1966 57
1967 59
1968 76
1969 85
1970 72
1971 94
1972 69
1973 102
1974 106
1975 120
1976 106
1977 126
1978 125
1979 132
1980 116
1981 107
1982 156
1983 157
1984 177
1985 187
1986 190
1987 189
1988 168
1989 230
1990 195
1991 203
1992 206
1993 169
1994 216
1995 217
1996 233
1997 221
1998 219
1999 214
2000 262
2001 207
2002 236
2003 252
2004 258
2005 265
2006 310
2007 298
2008 305
2009 310
2010 324
2011 317
2012 379
2013 349
2014 393
2015 346
2016 383
2017 322
2018 300
2019 336
2020 352
2021 321
2022 298
2023 42
Text availability
Article attribute
Article type
Publication date

Search Results

11,650 results
Results by year
Filters applied: . Clear all
Page 1
Melphalan Flufenamide (Melflufen): First Approval.
Dhillon S. Dhillon S. Drugs. 2021 Jun;81(8):963-969. doi: 10.1007/s40265-021-01522-0. Drugs. 2021. PMID: 33961277 Review.
It is an ethyl ester of a lipophilic dipeptide consisting of melphalan and para-fluoro-L-phenylalanine. Due to its lipophilicity, melphalan flufenamide is rapidly transported across the cell membrane and almost immediately hydrolyzed by aminopeptidases in the cytopl …
It is an ethyl ester of a lipophilic dipeptide consisting of melphalan and para-fluoro-L-phenylalanine. Due to its lipophilicity, …
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodríguez-Otero P, Leleu X, Richardson PG. Nadeem O, et al. Drugs Today (Barc). 2022 Aug;58(8):407-423. doi: 10.1358/dot.2022.58.8.3367680. Drugs Today (Barc). 2022. PMID: 35983927 Review.
Patients with relapsed/refractory MM (RRMM), especially those with triple-class-refractory disease or poor-prognostic features, have substantially unmet needs for new therapies with novel mechanisms of action. Melphalan flufenamide (melflufen) is the first alkylating pepti …
Patients with relapsed/refractory MM (RRMM), especially those with triple-class-refractory disease or poor-prognostic features, have substan …
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F, Tripepi G, Martino EA, Vigna E, Mendicino F, Morabito L, Todoerti K, Al-Janazreh H, D'Arrigo G, Canale FA, Cutrona G, Neri A, Martino M, Gentile M. Morabito F, et al. Drug Des Devel Ther. 2021 Jul 8;15:2969-2978. doi: 10.2147/DDDT.S295215. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34262262 Free PMC article. Review.
Despite recent therapeutic advances, multiple myeloma (MM) patients experience relapses as they become resistant to various classes and combinations of treatment. Melphalan (L-PAM) is an ageless drug. However, its use in the autologous stem cell transplantation (ASCT) sett …
Despite recent therapeutic advances, multiple myeloma (MM) patients experience relapses as they become resistant to various classes and comb …
Melphalan.
[No authors listed] [No authors listed] Rep Carcinog. 2004;11:III164. Rep Carcinog. 2004. PMID: 21089900 No abstract available.
Melphalan.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1990 Jan;7(1):35-6. doi: 10.1177/104345429000700110. J Pediatr Oncol Nurs. 1990. PMID: 2363868 No abstract available.
Oral melphalan kinetics.
Alberts DS, Chang SY, Chen HS, Evans TL, Moon TE. Alberts DS, et al. Clin Pharmacol Ther. 1979 Dec;26(6):737-45. doi: 10.1002/cpt1979266737. Clin Pharmacol Ther. 1979. PMID: 498715
Oral melphalan had a mean plasma terminal phase half-life (t1/2) of 90 +/- 17 min. ...In a myeloma patient who took oral melphalan, no melphalan was found in plasma or urine up to 24 hr. Some instances of failure of tumor response to oral melphalan may …
Oral melphalan had a mean plasma terminal phase half-life (t1/2) of 90 +/- 17 min. ...In a myeloma patient who took oral melphalan
Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis.
Francis JH, Gobin YP, Alshiekh Nasany R, Knopman J, Ulaner GA, Panageas KS, Hatzoglou V, Salvaggio K, Abramson DH, Patsalides A, Diamond EL. Francis JH, et al. Neurology. 2021 Jun 8;96(23):1091-1093. doi: 10.1212/WNL.0000000000012070. Epub 2021 May 12. Neurology. 2021. PMID: 33980709 Free PMC article. No abstract available.
High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review.
Varga C, Comenzo RL. Varga C, et al. Bone Marrow Transplant. 2019 Apr;54(4):508-518. doi: 10.1038/s41409-018-0284-4. Epub 2018 Aug 8. Bone Marrow Transplant. 2019. PMID: 30089901 Review.
The application of high-dose melphalan and autologous stem cell transplant (SCT) to systemic AL amyloidosis (AL) has evolved over the past two decades and remains an important component of therapy for patients with AL. ...In this review, we touch on the history of SCT for …
The application of high-dose melphalan and autologous stem cell transplant (SCT) to systemic AL amyloidosis (AL) has evolved over the …
Oral melphalan for the treatment of relapsed canine lymphoma.
Mastromauro ML, Suter SE, Hauck ML, Hess PR. Mastromauro ML, et al. Vet Comp Oncol. 2018 Mar;16(1):E123-E129. doi: 10.1111/vco.12356. Epub 2017 Sep 21. Vet Comp Oncol. 2018. PMID: 28941072
Oral melphalan has been included in multi-agent rescue protocols for canine lymphoma but its activity as a single-agent for this purpose has not been established. ...Retrospective evaluation of 19 cases of relapsed canine lymphoma treated with oral melphalan was per …
Oral melphalan has been included in multi-agent rescue protocols for canine lymphoma but its activity as a single-agent for this purp …
The systemic administration of intravenous melphalan.
Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. Sarosy G, et al. J Clin Oncol. 1988 Nov;6(11):1768-82. doi: 10.1200/JCO.1988.6.11.1768. J Clin Oncol. 1988. PMID: 3054005 Review.
In addition, unlike oral melphalan, an extensive phase I evaluation of IV melphalan has not been undertaken. ...Additional clinical trials will be necessary to define the spectrum of activity of lower doses of IV melphalan and to define subgroups of patients …
In addition, unlike oral melphalan, an extensive phase I evaluation of IV melphalan has not been undertaken. ...Additional cli …
11,650 results
You have reached the last available page of results. Please see the User Guide for more information.